A3
A39.F Arjo AB (publ)
- Market cap
- EUR 900M
- P/E
- 27.5x
- P/B
- 1.25x
- ROE
- 4.8%
- Dividend yield
- 2.62%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is A39.F undervalued?
Graham numberA39.F trades 23.4% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Arjo AB (publ) fundamental analysis
No fundamental analysis for Arjo AB (publ) yet.
Arjo AB (publ) stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Arjo AB (publ)
Arjo AB (publ) develops and sells medical devices and solutions for patients for clinical and financial outcomes for healthcare in Europe, Asia, Latin America, Africa, and the Pacific. It offers products and solutions for patient handling, hygiene, disinfection, medical beds, pressure injury prevention, diagnostics, hygiene, prevention of pressure injuries and blood clots, and leg ulcer treatment and prevention, as well as for obstetric and cardiac diagnostics. The company a…
Full company profileArjo AB (publ) financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Arjo AB (publ) annual financial statements (SEK; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 7.81B | 7.69B | 8.22B | 8.93B | 9.08B | 9.07B | 9.98B | 11.0B | 11.3B | 11.0B | 11.1B |
| Gross Profit | 3.44B | 3.43B | 3.66B | 3.89B | 4.13B | 4.21B | 4.21B | 4.74B | 4.91B | 4.69B | 4.72B |
| Operating Income | 943M | 605M | 609M | 725M | 943M | 1.12B | 774M | 984M | 1.03B | 831M | 863M |
| EBITDA | - | 1.01B | 1.19B | 1.68B | 1.82B | 2.03B | 1.79B | 1.96B | 2.01B | 1.77B | 1.95B |
| Net Income | 490M | 118M | 296M | 403M | 526M | 742M | 447M | 480M | 498M | 334M | 388M |
| EPS | - | 0.43 | 1.09 | 1.48 | 1.93 | 2.72 | 1.64 | 1.76 | 1.83 | 1.23 | 1.42 |
| Balance Sheet | |||||||||||
| Total Assets | 14.7B | 12.2B | 13.1B | 14.4B | 13.9B | 14.6B | 16.2B | 15.4B | 16.3B | 15.0B | 16.0B |
| Total Liabilities | 4.06B | 7.14B | 7.71B | 8.51B | 8.23B | 7.73B | 8.54B | 7.86B | 7.94B | 7.52B | 7.92B |
| Shareholders' Equity | 10.7B | 5.07B | 5.43B | 5.91B | 5.63B | 6.89B | 7.62B | 7.58B | 8.34B | 7.46B | 8.03B |
| Cash & Short-term Investments | 1.45B | 672M | 961M | 662M | 972M | 757M | 949M | 923M | 892M | 836M | 858M |
| Cash Flow | |||||||||||
| Operating Cash Flow | 919M | 572M | 991M | 1.25B | 2.27B | 1.73B | 915M | 1.85B | 1.52B | 1.44B | 1.31B |
| Capital Expenditure | 0.00 | 653M | 642M | 758M | 807M | 675M | 880M | 679M | 678M | 708M | 0.00 |
| Free Cash Flow | - | -81.0M | 349M | 494M | 1.46B | 974M | 15.0M | 948M | 838M | 727M | 1.31B |
| Ratios | |||||||||||
| ROE | 4.6% | 2.3% | 5.5% | 6.8% | 9.3% | 10.8% | 5.9% | 6.3% | 6.0% | 4.5% | 4.8% |
| ROA | 3.3% | 1.0% | 2.3% | 2.8% | 3.8% | 5.1% | 2.8% | 3.1% | 3.1% | 2.2% | 2.4% |
| Net Profit Margin | 6.3% | 1.5% | 3.6% | 4.5% | 5.8% | 8.2% | 4.5% | 4.4% | 4.4% | 3.0% | 3.5% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Arjo AB (publ) dividends
- Dividend yield
- 2.62%
- Forward dividend
- 0.09 EUR
- Payout ratio
- 77.5%
- Ex-dividend date
- Apr 23, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | SEK 259M | 0.95 | 77.5% |
| 2024 | SEK 245M | 0.90 | 49.2% |
| 2023 | SEK 232M | 0.85 | 48.3% |
| 2022 | SEK 313M | 1.15 | 70.0% |
| 2021 | SEK 232M | 0.85 | 31.3% |
| 2020 | EUR 177M | 0.65 | 33.7% |
| 2019 | EUR 150M | 0.55 | 37.2% |
| 2018 | EUR 136M | 0.50 | 45.9% |
| 2017 | EUR 136M | 0.50 | 115.3% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns Arjo AB (publ)
- Insiders 25.56%
- Institutions 40.10%
- Public & others 34.35%
- Shares outstanding 254M
- Free float 185M
Arjo AB (publ) company profile
- Company name
- Arjo AB (publ)
- Ticker
- A39.F
- ISIN
- SE0010468116
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Health Care Providers & Services
- Employees
- 7,000
- Fiscal year end
- December
- Address
- Hans Michelsensgatan 10, Malmö, Sweden, 201 20
- Phone
- 46 1 03 35 45 00
- Website
- arjo.com
About Arjo AB (publ)
Arjo AB (publ) develops and sells medical devices and solutions for patients for clinical and financial outcomes for healthcare in Europe, Asia, Latin America, Africa, and the Pacific. It offers products and solutions for patient handling, hygiene, disinfection, medical beds, pressure injury prevention, diagnostics, hygiene, prevention of pressure injuries and blood clots, and leg ulcer treatment and prevention, as well as for obstetric and cardiac diagnostics. The company also provides dementia care, bariatric room solutions, prone positioning, early mobility, architects and planners, and rehabilitation services, as well as equipment repair and maintenance, and equipment rental and financing solutions. It serves private and public institutions that provide acute and long-term care. Arjo AB (publ) was founded in 1957 and is headquartered in Malmö, Sweden.
Arjo AB (publ) management
10- Mr. Andreas ElgaardPresident, CEO & Director · born 1972
- Mr. Christofer CarlssonChief Financial Officer · born 1973
- Jonas CederhageExecutive Vice President of Product Development, Supply Chain & Operations · born 1971
- Sara EhingerVice President of Investor Relations & Corporate Communications
- Ms. Ingrid CarlssonExecutive VP of Legal & Business Compliance and Board Secretary · born 1976
- Ms. Marianne NilssonExecutive Vice President of Communication & Public Relations · born 1982
- Mr. Tobias KramerExecutive Vice President of Global Marketing · born 1984
- Ms. Eva BrikeExecutive VP of Human Resources & Sustainability · born 1968
- Mr. Johan OstbladHead of Sustainability
- Ms. Maria FagerbergExecutive Vice President of Quality & Regulatory Compliance · born 1977